Bococizumab is a novel anti-PCSK9 antibody specifically developed to address hypercholesterolemia. It therapeutic agent works by the PCSK9 protein, a key regulator of cholesterol levels. By neutralizing the activity of https://www.targetmol.com/compound/bococizumab